ADC Therapeutics SA (ADCT) Key Metrics
ADCT valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $178.7M
- Enterprise value
- $65.7M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 2.2 10-yr median 2.7
- Price / book
- 3.4 10-yr median 6.2
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.86
ADCT key metrics, 2017–2025
Fiscal year ended December 31, 2025 · U.S. dollarsADCT valuation Price multiples at each fiscal year-end price.
Price / sales+102.0%
5.5
2025 · hover or tap a bar for each year
20172025
Free cash flow yield+33.0 pts
−31.5%
2025 · hover or tap a bar for each year
20172025
ADCT returns How much profit the business earns on the capital it uses.
Return on assets+2.4 pts
−44.2%
2025 · hover or tap a bar for each year
20172025
Free cash flow margin+2.2 pts
−173.8%
2025 · hover or tap a bar for each year
20172025
Asset turnover+20.5%
0.25
2025 · hover or tap a bar for each year
20172025
ADCT per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−12.2%
$0.64
2025 · hover or tap a bar for each year
20172025
Earnings per share
−$1.12
2025 · hover or tap a bar for each year
20172025
Free cash flow per share
−$1.11
2025 · hover or tap a bar for each year
20172025
Book value per share
−$1.46
2025 · hover or tap a bar for each year
20172025
Shares outstanding+30.8%
127.1M
2025 · hover or tap a bar for each year
20172025
ADCT financial health Debt, liquidity and how easily interest is covered.
Net debt+$305.5M
$177.7M
2025 · hover or tap a bar for each year
20172025
Current ratio+14.3%
4.37
2025 · hover or tap a bar for each year
20172025
Interest coverage
-2.1
2025 · hover or tap a bar for each year
20172025
Debt / assets+255.6%
1.36
2025 · hover or tap a bar for each year
20172025
ADCT efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−6 days
111 days
2025 · hover or tap a bar for each year
20172025
Days of inventory−524 days
537 days
2025 · hover or tap a bar for each year
20172025
Days payables outstanding−384 days
647 days
2025 · hover or tap a bar for each year
20172025
Cash conversion cycle−146 days
1 days
2025 · hover or tap a bar for each year
20172025
Capex / revenue−0.9 pts
0.3%
2025 · hover or tap a bar for each year
20172025
ADCT valuation history
Fiscal year-endToday9-year median
ADCT returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ADCT debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ADCT cash returned to shareholders
DividendsBuybacksFree cash flow
ADCT price vs earnings per share
Share price at year-endEPS (right axis)
ADCT key metrics
2017–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Valuation | |||||||||
| Market capitalization | $448.5M | $193.3M | $135.6M | $300.1M | $1.55B | $2.09B | — | — | — |
| Enterprise value | $626.2M | $65.5M | −$18.6M | $103.5M | $1.22B | $1.77B | — | — | — |
| Price / sales | 5.5 | 2.7 | 2.0 | 1.4 | 45.7 | — | — | — | — |
| Price / book | — | — | — | 3.8 | 9.3 | 6.2 | — | — | — |
| EV / sales | 7.7 | 0.9 | -0.3 | 0.5 | 36.1 | — | — | — | — |
| Earnings yield | −31.8% | −81.6% | −177.0% | −52.4% | −14.8% | −11.8% | — | — | — |
| Free cash flow yield | −31.5% | −64.5% | −89.9% | −45.8% | −15.5% | −8.2% | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.1% | 0.0% | 0.0% | — | — | — |
| Share price at fiscal year-end | $3.53 | $1.99 | $1.66 | $3.84 | $20.20 | $32.01 | — | — | — |
| Per share | |||||||||
| Revenue per share | $0.64 | $0.73 | $0.85 | $2.69 | $0.44 | $0.00 | $0.03 | $0.02 | $0.03 |
| Earnings per share | −$1.12 | −$1.62 | −$2.94 | −$2.01 | −$3.00 | −$3.77 | −$1.74 | −$2.29 | −$1.53 |
| Operating cash flow per share | −$1.11 | −$1.27 | −$1.45 | −$1.75 | −$3.04 | −$2.58 | −$1.82 | −$2.25 | −$1.27 |
| Free cash flow per share | −$1.11 | −$1.28 | −$1.49 | −$1.76 | −$3.12 | −$2.62 | −$1.85 | −$2.30 | −$1.33 |
| Cash per share | $2.06 | $2.58 | $3.41 | $4.18 | $6.08 | $6.71 | $1.73 | $2.58 | $4.46 |
| Book value per share | −$1.46 | −$2.09 | −$1.81 | $1.02 | $2.16 | $5.13 | $1.66 | $2.35 | $4.23 |
| Tangible book value per share | −$1.46 | −$2.09 | −$1.81 | $0.83 | $1.99 | $4.97 | $1.54 | $2.22 | $4.14 |
| Capex per share | $0.00 | $0.01 | $0.04 | $0.01 | $0.08 | $0.04 | $0.03 | $0.05 | $0.05 |
| Debt per share | $3.45 | $1.27 | $1.52 | $1.66 | $1.82 | $1.76 | $0.08 | — | — |
| Shares outstanding | 127.1M | 97.2M | 81.7M | 78.2M | 76.7M | 65.4M | 66.9M | 53.8M | 58.9M |
| Change in shares outstanding | +30.8% | +18.9% | +4.6% | +1.8% | +17.3% | −2.2% | +24.2% | −8.5% | — |
| Returns & profitability | |||||||||
| Return on equity (ROE) | — | — | — | −128.0% | −91.7% | −110.3% | −98.1% | −65.6% | −36.1% |
| Return on assets (ROA) | −44.2% | −46.6% | −56.8% | −28.3% | −40.7% | −75.6% | −80.8% | −58.3% | −33.0% |
| Return on tangible assets | −44.1% | −49.0% | −67.7% | −33.0% | −38.1% | −48.9% | −90.1% | −85.6% | −33.7% |
| Free cash flow margin | −173.8% | −176.0% | −175.3% | −65.4% | −706.9% | — | — | — | — |
| Financial health | |||||||||
| Total debt | $439.0M | $123.0M | $124.4M | $129.8M | $139.7M | $115.1M | $5.0M | — | — |
| Cash & short-term investments | $261.3M | $250.9M | $278.6M | $326.4M | $466.5M | $439.2M | $115.6M | $138.8M | $262.8M |
| Net debt | $177.7M | −$127.9M | −$154.2M | −$196.6M | −$326.8M | −$324.1M | −$110.5M | −$138.8M | −$262.8M |
| Debt / equity | — | — | — | 1.63 | 0.84 | 0.34 | 0.05 | — | — |
| Debt / assets | 1.36 | 0.38 | 0.35 | 0.26 | 0.23 | 0.22 | 0.04 | — | — |
| Current ratio | 4.37 | 3.82 | 4.97 | 5.31 | 7.10 | 11.14 | 6.15 | 6.36 | 12.91 |
| Quick ratio | 4.31 | 3.59 | 4.73 | 5.16 | 6.95 | 10.98 | 6.02 | 6.30 | 12.89 |
| Interest coverage | -2.1 | -2.6 | -3.6 | -3.4 | -14.3 | -44.5 | -765.4 | -38.4 | -34.2 |
| Working capital | $236.2M | $226.9M | $268.6M | $353.0M | $451.2M | $410.0M | $102.7M | $119.7M | $244.6M |
| Invested capital | −$8.2M | −$330.5M | −$302.5M | −$117.1M | −$160.8M | $11.4M | $636,000 | −$12.6M | −$13.6M |
| Tangible asset value | −$185.8M | −$202.6M | −$148.2M | $65.1M | $152.5M | $325.3M | $102.7M | $119.6M | $243.8M |
| Net current asset value | −$202.6M | −$217.2M | −$166.7M | $23.6M | $73.3M | $272.3M | $96.1M | $117.8M | $242.4M |
| Graham net-net per share | −$1.76 | −$2.57 | −$2.42 | −$0.31 | $0.57 | $4.07 | $1.38 | $2.14 | $4.10 |
| Capital allocation | |||||||||
| Share buybacks (net) | — | — | — | $221,000 | $0 | $0 | $141,000 | $24,000 | $0 |
| Capex / revenue | 0.3% | 1.2% | 4.6% | 0.3% | 18.8% | — | 91.8% | 216.7% | 175.0% |
| Capex / depreciation | 0.14 | 0.26 | 0.98 | 0.24 | 2.42 | 1.42 | 1.30 | 3.34 | 9.26 |
| Stock-based compensation / revenue | 8.5% | 9.3% | 19.4% | 23.5% | 178.3% | — | 47.7% | 41.1% | 54.4% |
| R&D / revenue | 127.8% | 154.8% | 182.8% | 88.8% | 465.8% | — | 4,595.6% | 10,378.3% | 4,743.8% |
| SG&A / revenue | 98.2% | 121.3% | 152.2% | 68.4% | 401.7% | — | 606.9% | 754.6% | 432.9% |
| Efficiency | |||||||||
| Days sales outstanding | 110.9 | 117.2 | 257.5 | 90.4 | 181.6 | — | 250.5 | 368.0 | 390.1 |
| Days of inventory on hand | 536.8 | 1,060.3 | 2,038.6 | 1,282.4 | 2,308.6 | 11.5 | 6.2 | 2.3 | 1.3 |
| Days payables outstanding | 647.0 | 1,030.7 | 2,014.8 | 1,350.7 | 2,274.2 | 11.1 | 17.1 | 22.2 | 32.5 |
| Cash conversion cycle (days) | 0.7 | 146.9 | 281.3 | 22.1 | 215.9 | — | 239.6 | 348.1 | 358.8 |
| Receivables turnover | 3.29 | 3.11 | 1.42 | 4.04 | 2.01 | 0.00 | 1.46 | 0.99 | 0.94 |
| Payables turnover | 0.56 | 0.35 | 0.18 | 0.27 | 0.16 | 32.95 | 21.34 | 16.44 | 11.23 |
| Inventory turnover | 0.68 | 0.34 | 0.18 | 0.28 | 0.16 | 31.62 | 58.51 | 157.76 | 291.91 |
| Asset turnover | 0.25 | 0.21 | 0.16 | 0.38 | 0.06 | 0.00 | 0.02 | 0.01 | 0.01 |
| Average receivables | $24.7M | $22.7M | $49.1M | $52.0M | $16.9M | $2.8M | $1.6M | $1.1M | $1.9M |
| Average payables | $13.6M | $16.8M | $14.0M | $12.2M | $8.7M | $4.3M | $5.0M | $7.2M | $7.6M |
| Average inventory | $11.3M | $17.3M | $14.1M | $11.6M | $8.8M | $4.5M | $1.8M | $748,500 | $293,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 2.9% | 2.2% | 2.0% | 6.1% | 4.4% | 2.0% |
Computed from ADCT's annual financial statements (latest annual report filed March 10, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ADCT valuation and financial ratios
It ended the year with $439.0 million of debt and $261.3 million in cash and short-term investments, net debt of $177.7 million. The share count rose 115.9% from 58.9M to 127.1M over 8 years.
See the ADCT income statement, the ADCT chart for price history, or the ADCT stock overview for the latest quote and news.
ADCT key metrics FAQ
How much debt does ADC Therapeutics have?
ADC Therapeutics had total debt of $439.0 million at the end of fiscal 2025.
What is ADC Therapeutics's free cash flow yield?
ADC Therapeutics generated -$141.4 million of free cash flow in fiscal 2025, a free cash flow yield of −31.5% on its market value at year-end ($448.5 million).
What is ADC Therapeutics's current ratio?
ADC Therapeutics's current ratio was 4.37 at the end of fiscal 2025: current assets were 4.37 times current liabilities.